Member Info for Andysel

looking forward to a very steady flow of positive news coming out of Val

*25th November

yep, RNS 21st November confirming the signed deal, then re-focus the business in december on other matters with a Q&A following an RNS update on some/one of the female targeted projects, that how i read this latest RNS

Now these sessions are taking place I would expect RNS's out on the same days too with official updates, this is being pro-active which is fantastic.

@roace
The question you refer to asked by Adam was asked after the recording stopped, it was way too scientific for me to understand what they were talking about, but I don’t think that session was recorded

a very good informative read

its worth remembering that this share is still up over 60% compared with a couple of months ago, and a full deal to be signed before the end of 2021, so all heading in the right direction still

nothing wrong with a cart horse AIR, they have so much stamina and just keep going until they reach their destination, they are so strong

just seems strange we've gone from little/no trades to more than a couple over the last few trading days, maybe someone does know something and news is about to drop

just had a look myself with lloyds and it won't give me a price for 1m shares, previously they couldn't wait to take my money for them

@ant.
i have never predicted an SP, i don't do that, the SP will eventually take care of itself,

Post 3
“The LOI details a period of exclusivity during which TheoremRx will complete its due diligence on the scientific and commercial attributes of VAL201, during which ValiRx is restricted from continuing to market the programme to other parties. Completion of the Licence Agreement is also subject to terms and conditions at closing.”

This is normal practice, the majority of the evaluation will have been done over the last 6-10 months as part of the process to get to this stage, the final part of the stage is to do the due diligence on the contracts to dot the I’s and cross the t’s to enable funding to be released. – lets face it no one will part with money if the contracts are not water tight

“The LOI and proposed Licence Agreement therefore remain non-binding and there is no guarantee that this Licence Agreement will be executed or that it will generate material revenues within the expected timeframe or at all.”

“This statement will appear on every initial LOI or MOU that has been entered into by many other companies on AIM that have led to full contracts, legally they have to insert this paragraph”

Dr Suzy Dilly, CEO of ValiRx commented: "Selecting a commercial partner for VAL201 with the right skills, experience and commitment has been a high priority for ValiRx. I am delighted that the team at TheoremRx has really taken the time to understand the science, the additional development needs and the commercial opportunity for VAL201 in oncology. I am looking forward to seeing the programme progress efficiently through the clinical development plan in their hands."
Dr Ken Sorensen, Chairman of TheoremRx stated: "We are very excited to be pursuing an agreement with ValiRx, a company with extensive and proven experience in research and drug development. We look forward to working towards a final agreement and seeing this technology occupy a preeminent position in the market for treating different cancers."

The last 2 paragraphs are from the people that really know what is in the contracts and more details of how this will be taken forward, I would tend to believe these two people over and above someone behind a fake name on a forum board.

Post 2
“Each oncology indication successfully developed to by TheoremRx will generate up to $37.5M of additional value to ValiRx.”
Just another 3 indications identified buy TheroemRX for VAL201 will take the generated value of the deal to $173.5m
“The proposed deal structure comprises payments on signature of the Licence Agreement plus fees and near-term milestones totalling US$2.2M before the end of 2023, milestones on further clinical and commercial development events, and royalties. The first payments are expected by the end of 2021.”
$2,2m up to 2023 with the first payment upon signing the contract before the end of 2021 has been confirmed as these dates form part of a binding LOI – it is unclear how much the initial payment will be, however VAL are fully funded until the middle of next year even without this additional income stream
“As part of the deal, TheoremRx will enter into a service contract with ValiRx to provide consulting services to TheoremRx to aid technology transfer, formulation for patent extension and continued clinical development of VAL201.”
TheroemRx will pay VAL on a monthly basis for ongoing work and advice, this has already started and is another addition to Val’s income stream

Post 1
I have taken the time to read, interpret and listen to many views about the agreement before putting together this post, however the only Statements that should be used are those from the RNS and then the clarification from ValiRX in terms of actual factual statements.

in the next few posts i have added statements that have bene confirmed in various interviews to the RNS for some clarity.

“London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, announces today it has entered into a non-binding letter of intent ("LOI") with TheoremRx Inc. ("TheoremRx"), a recently incorporated company, a next generation drug development Company, to enter into a licence agreement on pre-agreed terms to sub-license ValiRx's legacy asset VAL201 for development in the treatment of cancer (the "Licence Agreement"). Completion of the Licence Agreement is subject to, inter alia, the successful fundraise by TheoremRx.”
As is normal for this type of start up venture, the funding is dependent upon the company having a product, the LOI is needed to contractually confirm the product is theirs to use on condition of funding, you can’t get one without the other – We should not see funding as an issue for TheoremRx.
TheoremRX is not the same company some were posting links to, lets face it DR Ken Sorensen is not called Theo who is the gentleman on the website that others posted links to.
“TheoremRx is private US-based oncology company focused on the discovery and development of new treatments that will benefit patients suffering from cancer. TheoremRx has established a highly integrated approach for the discovery, development and manufacture of peptide and small molecule drugs that modulate targets of clinical interest.”
Suzy is a scientist and has been impressed with the discussions and level of knowledge the Team of industry professionals at TheoremRx have displayed
“Under this proposed Licence Agreement, TheoremRx will obtain a worldwide licence to ValiRx's VAL201 intellectual property for a novel peptide targeting SRC kinase targeting oncology indications. ValiRx will retain the rights to develop the VAL201 peptide for non-oncology indications, including VAL301 for endometriosis.”
Currently 301 is subject to works being carried out by a Japanese Pharma company and could lead to a completely separate agreement which would be an additional income stream in the future.
“Subject to successful market authorisation, the potential value of the deal would be in excess of US$61M plus royalties for the first cancer indication alone.”
A small focused team form a hungry company will be more likely to take this to market quicker than a big pharma, in addition it was confirmed that time lines and dates for the project have bene confirmed within the contracts and LOI, again bringing focus to the project.
Royalties on top of this will be in the high single figures meaning anywhere between 5-9%

thats correct. the LOI allows theorem to raise the funds, the contracts will then be signed and the first payment made this year + any consultancy fees that they will also be liable for for the work VAL do for theorem

its important that when the recording of the interview/QA is released shortly that it is tweeted and retweet by as many people as possible to dispel the misleading comments that filled this forum yesterday is

i thought the free float was nearer 50m so that would be 20% traded, although there are a lot of the free float with people that won't sell so the free float is probably lower than this

from memory, didn't the CRMC already have the plant at one of their facilities that was suitable following some trials, and that it was a case of digging the material out of the ground and transporting the rocks to the plant by truck for processing, this was the set up was minimal cost to get to production. i could be wrong, but i'm sure i read this in one of the RNS's

i would tend to agree with you OTUP

Personally i think the funding has already been agreed in principle and the investors want TheoremRx to have a cast iron guarantee offering of the the product first, hence the LOI confirming its theirs when funding is in place,
This is the process they follow in the USA for funding start ups, the due diligence mentioned will not be on the product, that will have already been assessed, the du-dil will likely be the wording of the contracts etc. to release the funds, this is my opinion, that is why Suzy has said first payment before the end of the year